Small molecule inhibitors of BRAF in clinical trials (original) (raw)

Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial

Luis De la cruz

Nature Communications, 2021

View PDFchevron_right

Recent developments and obstacles in the treatment of melanoma with BRAF and MEK inhibitors

Mohtashim Lohani

Critical reviews in oncology/hematology, 2018

View PDFchevron_right

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

Daniil Stroyakovskiy, Evgeny V Levchenko

New England Journal of Medicine, 2014

View PDFchevron_right

BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies

Francesco Spagnolo, Paola Ghiorzo

OncoTargets and Therapy, 2015

View PDFchevron_right

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma

Alexander Menzies

British journal of cancer, 2013

View PDFchevron_right

Major Clinical Response to a BRAF Inhibitor in a Patient With a BRAF L597R–Mutated Melanoma

Damien Giacchero

Journal of Clinical Oncology, 2013

View PDFchevron_right

Current Advances in the Treatment of BRAF-Mutant Melanoma

Samar Alanazi

Cancers

View PDFchevron_right

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Igor Puzanov

New England Journal of Medicine, 2010

View PDFchevron_right

Targeting the Cellular Signaling: BRAF Inhibition and Beyond for the Treatment of Metastatic Malignant Melanoma

Felipe Ades

2012

View PDFchevron_right

BRAF in malignant melanoma progression and metastasis: potentials and challenges

Aljawharah Alqathama

American journal of cancer research, 2020

View PDFchevron_right

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

Daniele Ouellet

New England Journal of Medicine, 2012

View PDFchevron_right

Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma

Paolo Ascierto

Journal of Clinical Oncology, 2013

View PDFchevron_right

Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma

Sara Tomei, Lucia Gemma Delogu

Expert Opinion on Biological Therapy, 2014

View PDFchevron_right

Targeted Therapy for Melanomas Without BRAF V600 Mutations

Christian Menzer

Current Treatment Options in Oncology, 2022

View PDFchevron_right

RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models

Joseph Grippo

Cancer Research, 2010

View PDFchevron_right

The multifaceted anti-cancer effects of BRAF-inhibitors

Laura Croce

Oncotarget

View PDFchevron_right

Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas

Emanuel Petricoin

Oncotarget, 2015

View PDFchevron_right

Good clinical and radiological response to BRAF inhibitor in patient with metastatic thin melanoma

Fintan Wallis

Case Reports, 2012

View PDFchevron_right

Melanoma Targeted Therapies beyond BRAF-Mutant Melanoma: Potential Druggable Mutations and Novel Treatment Approaches

Ana Avila-Rodriguez, Yazan Maamar, Sami Samaan

Cancers, 2021

View PDFchevron_right

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma

Francesco Spagnolo

Oncotarget, 2014

View PDFchevron_right

The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance

Peter Hersey

Carcinogenesis, 2013

View PDFchevron_right

Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations

Christian Menzer

Journal of Clinical Oncology

View PDFchevron_right

BRAF inhibitors: From the laboratory to clinical trials

Alfred Lam

Critical Reviews in Oncology/Hematology, 2013

View PDFchevron_right

The Role of BPTF in Melanoma Progression and in Response to BRAF-Targeted Therapy

Altaf Dar

JNCI: Journal of the National Cancer Institute, 2015

View PDFchevron_right

Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review

Catherine Rees

Cancers, 2020

View PDFchevron_right

Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma

Teofila Caplanusi

Melanoma Research, 2015

View PDFchevron_right

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

Brian West

Nature, 2010

View PDFchevron_right